

Audit Review Table					
Presbyterian Health Plan, Inc. (Org ID: 579, Sub ID: 4104, Medicaid, Spec Area: None, Spec Proj: None, Contract Number: None)					
Measurement Year - 2022; Date & Timestamp - 6/7/2023 10:06:15 AM					
This submission is on the stage: Submission Finalized					
Measure/Data Element	Benefit Offered	Rate	Status	Audit Designation	Comment
Effectiveness of Care					
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC)					
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - BMI percentile (Total)		75.31%	R	R	Reported
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - Counseling for Nutrition (Total)		61.60%	R	R	Reported
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - Counseling for Physical Activity (Total)		58.35%	R	R	Reported
Childhood Immunization Status (CIS)					
Childhood Immunization Status - DTaP		75.67%	R	R	Reported
Childhood Immunization Status - IPV		87.35%	R	R	Reported
Childhood Immunization Status - MMR		89.05%	R	R	Reported
Childhood Immunization Status - Hib		85.89%	R	R	Reported
Childhood Immunization Status - Hepatitis B		91.73%	R	R	Reported
Childhood Immunization Status - VZV		85.89%	R	R	Reported
Childhood Immunization Status - Pneumococcal Conjugate		76.64%	R	R	Reported
Childhood Immunization Status - Hepatitis A		85.89%	R	R	Reported
Childhood Immunization Status - Rotavirus		75.91%	R	R	Reported
Childhood Immunization Status - Influenza		50.12%	R	R	Reported
Childhood Immunization Status - Combo 3		70.56%	R	R	Reported
Childhood Immunization Status - Combo 7		65.94%	R	R	Reported
Childhood Immunization Status - Combo 10		42.58%	R	R	Reported
Immunizations for Adolescents (IMA)					
Immunizations for Adolescents - Meningococcal		84.18%	R	R	Reported
Immunizations for Adolescents - Tdap		86.13%	R	R	Reported
Immunizations for Adolescents - HPV		35.77%	R	R	Reported
Immunizations for Adolescents - Combination 1		83.94%	R	R	Reported
Immunizations for Adolescents - Combination 2		35.52%	R	R	Reported
Lead Screening in Children (LSC)					
Lead Screening in Children		34.79%	R	R	Reported
Breast Cancer Screening (BCS)					
Breast Cancer Screening		39.92%	R	R	Reported
Cervical Cancer Screening (CCS)					
Cervical Cancer Screening		48.66%	R	R	Reported
Colorectal Cancer Screening (COL)					
Colorectal Cancer Screening (Total)		29.64%	R	R	Reported
Chlamydia Screening in Women (CHL)					
Chlamydia Screening in Women (Total)		47.76%	R	R	Reported
Appropriate Testing for Pharyngitis (CWP)					
Appropriate Testing for Pharyngitis (Total)	Y	76.51%	R	R	Reported
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)					
Use of Spirometry Testing in the Assessment and Diagnosis of COPD		17.88%	R	R	Reported
Pharmacotherapy Management of COPD Exacerbation (PCE)					
Pharmacotherapy Management of COPD Exacerbation - Systemic Corticosteroid	Y	54.42%	R	R	Reported
Pharmacotherapy Management of COPD Exacerbation - Bronchodilator		63.67%	R	R	Reported
Asthma Medication Ratio (AMR)					
Asthma Medication Ratio (Total)	Y	73.13%	R	R	Reported
Controlling High Blood Pressure (CBP)					
Controlling High Blood Pressure		52.59%	R	R	Reported
Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)					
Persistence of Beta-Blocker Treatment After a Heart Attack	Y	70.06%	R	R	Reported
Statin Therapy for Patients With Cardiovascular Disease (SPC)					
Statin Therapy for Patients With Cardiovascular Disease - Received Statin Therapy (Total)	Y	63.27%	R	R	Reported
Statin Therapy for Patients With Cardiovascular Disease - Statin Adherence 80% (Total)		64.77%	R	R	Reported
Cardiac Rehabilitation (CRE)					
Cardiac Rehabilitation - Initiation (Total)		0.92%	R	R	Reported
Cardiac Rehabilitation - Engagement1 (Total)		3.49%	R	R	Reported
Cardiac Rehabilitation - Engagement2 (Total)		3.13%	R	R	Reported
Cardiac Rehabilitation - Achievement (Total)		1.10%	R	R	Reported
Hemoglobin A1c Control for Patients With Diabetes (HBD)					

Hemoglobin A1c Control for Patients With Diabetes - HbA1c Control (<8%)		40.88%	R	R	Reported
Hemoglobin A1c Control for Patients With Diabetes - Poor HbA1c Control		52.31%	R	R	Reported
Blood Pressure Control for Patients With Diabetes (BPD)					
Blood Pressure Control for Patients With Diabetes		54.26%	R	R	Reported
Eye Exam for Patients With Diabetes (EED)					
Eye Exam for Patients With Diabetes		39.17%	R	R	Reported
Kidney Health Evaluation for Patients With Diabetes (KED)					
Kidney Health Evaluation for Patients With Diabetes (Total)		33.51%	R	R	Reported
Statin Therapy for Patients With Diabetes (SPD)	Y				
Statin Therapy for Patients With Diabetes - Received Statin Therapy		50.54%	R	R	Reported
Statin Therapy for Patients With Diabetes - Statin Adherence 80%		61.35%	R	R	Reported
Diagnosed Mental Health Disorders (DMH)					
Diagnosed Mental Health Disorders (Total)		26.34%	R	R	Reported
Antidepressant Medication Management (AMM)	Y				
Antidepressant Medication Management - Effective Acute Phase Treatment		61.99%	R	R	Reported
Antidepressant Medication Management - Effective Continuation Phase Treatment		42.33%	R	R	Reported
Follow-Up Care for Children Prescribed ADHD Medication (ADD)	Y				
Follow-Up Care for Children Prescribed ADHD Medication - Initiation Phase		28.73%	R	R	Reported
Follow-Up Care for Children Prescribed ADHD Medication - Continuation and Maintenance Phase		36.73%	R	R	Reported
Follow-Up After Hospitalization for Mental Illness (FUH)	Y				
Follow-Up After Hospitalization For Mental Illness - 30 days (Total)		55.03%	R	R	Reported
Follow-Up After Hospitalization For Mental Illness - 7 days (Total)		35.14%	R	R	Reported
Follow-Up After Emergency Department Visit for Mental Illness (FUM)	Y				
Follow-Up After Emergency Department Visit for Mental Illness - 30 days (Total)		59.36%	R	R	Reported
Follow-Up After Emergency Department Visit for Mental Illness - 7 days (Total)		45.59%	R	R	Reported
Diagnosed Substance Use Disorders (DSU)					
Diagnosed Substance Use Disorders - Alcohol (Total)		4.25%	R	R	Reported
Diagnosed Substance Use Disorders - Opioid (Total)		3.33%	R	R	Reported
Diagnosed Substance Use Disorders - Other (Total)		4.26%	R	R	Reported
Diagnosed Substance Use Disorders - Any (Total)		9.14%	R	R	Reported
Follow-Up After High-Intensity Care for Substance Use Disorder (FUJ)	Y				
Follow-Up After High-Intensity Care for Substance Use Disorder - 30 days (Total)		42.04%	R	R	Reported
Follow-Up After High-Intensity Care for Substance Use Disorder - 7 Days (Total)		20.72%	R	R	Reported
Follow-Up After Emergency Department Visit for Substance Use (FUA)	Y				
Follow-Up After Emergency Department Visit for Substance Use - 30 days (Total)		34.98%	R	R	Reported
Follow-Up After Emergency Department Visit for Substance Use - 7 days (Total)		23.57%	R	R	Reported
Pharmacotherapy for Opioid Use Disorder (POD)	Y				
Pharmacotherapy for Opioid Use Disorder (Total)		17.72%	R	R	Reported
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)	Y				
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications		80.59%	R	R	Reported
Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)					
Diabetes Monitoring for People With Diabetes and Schizophrenia		64.08%	R	R	Reported
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)					
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia		73.53%	R	R	Reported
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)	Y				
Adherence to Antipsychotic Medications for Individuals With Schizophrenia		55.02%	R	R	Reported
Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM)	Y				
Metabolic Monitoring for Children and Adolescents on Antipsychotics - Blood Glucose Testing (Total)		60.65%	R	R	Reported
Metabolic Monitoring for Children and Adolescents on Antipsychotics - Cholesterol Testing (Total)		39.23%	R	R	Reported
Metabolic Monitoring for Children and Adolescents on Antipsychotics - Blood Glucose and Cholesterol Testing (Total)		38.19%	R	R	Reported
Non-Recommended Cervical Cancer Screening in Adolescent Females (NCS)					

<i>Non-Recommended Cervical Cancer Screening in Adolescent Females</i>		0.37%	R	R	Reported
Appropriate Treatment for Upper Respiratory Infection (URI)	Y				
<i>Appropriate Treatment for Upper Respiratory Infection (Total)</i>		84.39%	R	R	Reported
Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB)	Y				
<i>Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (Total)</i>		58.11%	R	R	Reported
Use of Imaging Studies for Low Back Pain (LBP)					
<i>Use of Imaging Studies for Low Back Pain (Total)</i>		73.58%	R	R	Reported
Use of Opioids at High Dosage (HDO)	Y				
<i>Use of Opioids at High Dosage</i>		4.12%	R	R	Reported
Use of Opioids From Multiple Providers (UOP)	Y				
<i>Use of Opioids From Multiple Providers - Multiple Prescribers</i>		15.09%	R	R	Reported
<i>Use of Opioids From Multiple Providers - Multiple Pharmacies</i>		1.85%	R	R	Reported
<i>Use of Opioids From Multiple Providers - Multiple Prescribers and Multiple Pharmacies</i>		0.77%	R	R	Reported
Risk of Continued Opioid Use (COU)	Y				
<i>Risk of Continued Opioid Use - >=15 Days (Total)</i>		4.85%	R	R	Reported
<i>Risk of Continued Opioid Use - >=31 Days (Total)</i>		3.48%	R	R	Reported
Access/Availability of Care					
Adults' Access to Preventive/Ambulatory Health Services (AAP)					
<i>Adults' Access to Preventive/Ambulatory Health Services (Total)</i>		73.39%	R	R	Reported
Annual Dental Visit (ADV)	Y				
<i>Annual Dental Visit (Total)</i>		61.06%	R	R	Reported
Initiation and Engagement of Substance Use Disorder Treatment (IET)	Y				
<i>Initiation and Engagement of Substance Use Disorder Treatment - Initiation of SUD Treatment - Total (Total)</i>		55.10%	R	R	Reported
<i>Initiation and Engagement of Substance Use Disorder Treatment - Engagement of SUD Treatment - Total (Total)</i>		22.73%	R	R	Reported
Prenatal and Postpartum Care (PPC)					
<i>Prenatal and Postpartum Care - Timeliness of Prenatal Care</i>		78.14%	R	R	Reported
<i>Prenatal and Postpartum Care - Postpartum Care</i>		72.95%	R	R	Reported
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP)	Y				
<i>Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (Total)</i>		62.36%	R	R	Reported
Utilization and Risk Adjusted Utilization					
Well-Child Visits in the First 30 Months of Life (W30)					
<i>Well-Child Visits in the First 30 Months of Life (First 15 Months)</i>		65.98%	R	R	Reported
<i>Well-Child Visits in the First 30 Months of Life (15 Months-30 Months)</i>		68.68%	R	R	Reported
Child and Adolescent Well-Care Visits (WCV)					
<i>Child and Adolescent Well-Care Visits (Total)</i>		44.45%	R	R	Reported
Frequency of Selected Procedures (FSP)			R	R	Reported
Ambulatory Care (AMB)			R	R	Reported
Inpatient Utilization - General Hospital/Acute Care (IPU)			R	R	Reported
Antibiotic Utilization for Respiratory Conditions (AXR)	Y				
<i>Antibiotic Utilization for Respiratory Conditions (Total)</i>		20.61%	R	R	Reported
Plan All-Cause Readmissions (PCR)			R	R	Reported
Health Plan Descriptive Information					
Enrollment by Product Line (ENP)			R	R	Reported
Language Diversity of Membership (LDM)			R	R	Reported
Race/Ethnicity Diversity of Membership (RDM)			R	R	Reported
Measures Reported Using Electronic Clinical Data Systems					
Childhood Immunization Status (CIS-E)					
<i>Childhood Immunization Status - DTaP</i>		52.58%	R	R	Reported
<i>Childhood Immunization Status - IPV</i>		67.80%	R	R	Reported
<i>Childhood Immunization Status - MMR</i>		72.51%	R	R	Reported
<i>Childhood Immunization Status - HiB</i>		67.84%	R	R	Reported
<i>Childhood Immunization Status - Hepatitis B</i>		58.89%	R	R	Reported
<i>Childhood Immunization Status - VZV</i>		71.59%	R	R	Reported
<i>Childhood Immunization Status - Pneumococcal Conjugate</i>		55.19%	R	R	Reported
<i>Childhood Immunization Status - Hepatitis A</i>		73.30%	R	R	Reported
<i>Childhood Immunization Status - Rotavirus</i>		59.29%	R	R	Reported
<i>Childhood Immunization Status - Influenza</i>		36.07%	R	R	Reported
<i>Childhood Immunization Status - Combo 3</i>		40.23%	R	R	Reported
<i>Childhood Immunization Status - Combo 7</i>		37.11%	R	R	Reported
<i>Childhood Immunization Status - Combo 10</i>		20.84%	R	R	Reported
Immunizations for Adolescents (IMA-E)					
<i>Immunizations for Adolescents - Meningococcal</i>		63.92%	R	R	Reported
<i>Immunizations for Adolescents - Tdap</i>		67.36%	R	R	Reported
<i>Immunizations for Adolescents - HPV</i>		26.48%	R	R	Reported
<i>Immunizations for Adolescents - Combination 1</i>		62.28%	R	R	Reported

<i>Immunizations for Adolescents - Combination 2</i>		25.47%	R	R	Reported
Breast Cancer Screening (BCS-E)					
<i>Breast Cancer Screening</i>		38.71%	R	R	Reported
Colorectal Cancer Screening (COL-E)					
<i>Colorectal Cancer Screening (Total)</i>		25.99%	R	R	Reported
Follow-Up Care for Children Prescribed ADHD Medication (ADD-E)	Y				
<i>Follow-Up Care for Children Prescribed ADHD Medication - Initiation Phase</i>		28.73%	R	R	Reported
<i>Follow-Up Care for Children Prescribed ADHD Medication - Continuation and Maintenance Phase</i>		36.73%	R	R	Reported
Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E)	Y				
<i>Metabolic Monitoring for Children and Adolescents on Antipsychotics - Blood Glucose Testing (Total)</i>		57.84%	R	R	Reported
<i>Metabolic Monitoring for Children and Adolescents on Antipsychotics - Cholesterol Testing (Total)</i>		31.48%	R	R	Reported
<i>Metabolic Monitoring for Children and Adolescents on Antipsychotics - Blood Glucose and Cholesterol Testing (Total)</i>		30.69%	R	R	Reported
Depression Screening and Follow-Up for Adolescents and Adults (DSF-E)					
<i>Depression Screening and Follow-Up for Adolescents and Adults - Depression Screening (Total)</i>		19.72%	R	R	Reported
<i>Depression Screening and Follow-Up for Adolescents and Adults - Follow-Up on Positive Screen (Total)</i>		74.48%	R	R	Reported
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E)					
<i>Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults - Utilization of PHQ-9-Total (Total)</i>		16.58%	R	R	Reported
Depression Remission or Response for Adolescents and Adults (DRR-E)					
<i>Depression Remission or Response for Adolescents and Adults - Follow-Up PHQ-9 (Total)</i>		54.87%	R	R	Reported
<i>Depression Remission or Response for Adolescents and Adults - Depression Remission (Total)</i>		18.58%	R	R	Reported
<i>Depression Remission or Response for Adolescents and Adults - Depression Response (Total)</i>		26.42%	R	R	Reported
Unhealthy Alcohol Use Screening and Follow-Up (ASF-E)					
<i>Unhealthy Alcohol Use Screening and Follow-Up - Unhealthy Alcohol Use Screening (Total)</i>		0.00%	R	R	Reported
<i>Unhealthy Alcohol Use Screening and Follow-Up - Alcohol Counseling or Other Follow-Up Care (Total)</i>			NA	R	Reported
Adult Immunization Status (AIS-E)					
<i>Adult Immunization Status - Influenza (19-65)</i>		9.18%	R	R	Reported
<i>Adult Immunization Status - Td/Tdap (19-65)</i>		32.77%	R	R	Reported
<i>Adult Immunization Status - Zoster (50-65)</i>		5.47%	R	R	Reported
Prenatal Immunization Status (PRS-E)					
<i>Prenatal Immunization Status - Influenza</i>		28.58%	R	R	Reported
<i>Prenatal Immunization Status - Tdap</i>		57.85%	R	R	Reported
<i>Prenatal Immunization Status - Combination</i>		24.58%	R	R	Reported
Prenatal Depression Screening and Follow-Up (PND-E)					
<i>Prenatal Depression Screening and Follow-Up - Depression Screening</i>		36.20%	R	R	Reported
<i>Prenatal Depression Screening and Follow-Up - Follow-Up on Positive Screen</i>		54.90%	R	R	Reported
Postpartum Depression Screening and Follow-Up (PDS-E)					
<i>Postpartum Depression Screening and Follow-Up - Depression Screening</i>		19.22%	R	R	Reported
<i>Postpartum Depression Screening and Follow-Up - Follow-Up on Positive Screen</i>		82.35%	R	R	Reported